ArticleAlzheimer's & dementia (New York, N. Y.)
Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY-AD and TRAILBLAZER-ALZ2.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Sex and APOE genotype specific brain regional vulnerability to Alzheimer's Disease.GeroScience · 2026Article
- Blood-based biomarkers and early diagnosis of Alzheimer's disease.Neural regeneration research · 2026Article
- Descriptive Analysis of Retrospective Observational Real-World Evidence of a Monoclonal Anti-Amyloid Therapy Program in a Wide Catchment Specialty Memory Clinic.Neurology and therapy · 2026Article
- The Neurology of Menopause.Current neurology and neuroscience reports · 2026Review
- Considerations in Alzheimer's Disease in Women.Current neurology and neuroscience reports · 2026Review
- Twenty years of sex and gender science in health research: a policy statement from the Organization for the Study of Sex Differences.Biology of sex differences · 2026Review
- Insights into the Impact of Low-Dose Ionizing Radiation on Neurodegenerative Disease Progression in In Vivo Models.International journal of molecular sciences · 2026Review
- Sex Differences in Metabolite-Immune Circuits of Neuroinflammation.Immunological reviews · 2026Review
- Sex differences in efficacy/safety of anti-amyloid-beta monoclonal antibodies for the treatment of Alzheimer's disease.Translational and clinical pharmacology · 2025Review
- Single-subject proteomic signatures in Alzheimer's disease reflect clinical phenotypes and distinguish asymptomatic from symptomatic cases.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study investigated evidence for or against a difference in treatment effect between women and men for lecanemab and donanemab.
methodsData were derived from supplementary analyses of the regulatory studies CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab). Bayes factor functions were used to analyze treatment effects on Clinical Dementia Rating Sum of Boxes (CDR-SB) scores.
resultsWe found moderate evidence of a lower treatment effect in women than in men for lecanemab (maximum Bayes factor = 5.97), suggesting that the presence of an effect was almost six times more likely than the absence of an effect. For donanemab, there was evidence against a treatment effect difference between women and men. There was evidence of a treatment effect difference between lecanemab and donanemab (maximum Bayes factor = 8.47) in women, but not in men. DISCUSSION: A better understanding of sex differences in treatment efficacy and their causes is urgently needed. Highlights: Lecanemab was six times more likely to be ineffective than effective in women.There was no evidence of a difference between the sexes in the effect of donanemab.Lecanemab and donenamb differed in treatment efficacy in women but not in men.Future trials should include sufficient power for sex related interaction effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.